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Abstract
Enterococci are among the leading pathogens isolated in hospital-acquired infections. Current antimicrobial options for vancomycin-resistant enterococci (VRE) are limited. Prior data suggests that daptomycin >
6mg/kg/day may be used to treat enterococcal infections. We retrospectively evaluated the effectiveness and safety
of high-dose daptomycin (HD-daptomycin) therapy (> 6 mg/kg) in a multicenter cohort of adult patients with enterococcal infections to describe the characteristics and outcomes. Two-hundred and forty-five patients were evaluated.
Enterococcus faecium was identified in 175 (71%), followed by 49 (20%) Enterococcus faecalis and 21 (9%) Enterococcus spp., overall 204 (83%) were VRE. Enterococcal infections included bacteremia (173, 71%), intraabdominal (35, 14%) and bone/joint (25, 10%). The median dose and duration of HD-daptomycin was 8.2
mg/kg/day (IQR 7.7-9.7) and 10 days (IQR 6-15), respectively. Overall clinical success rate was 89% (193/218) and
microbiological eradication was observed in 93% (177/191) of patients. The median time to clearance of blood cultures on HD-daptomycin was 3 days (IQR 2-5). Thirty-day all cause mortality rate was 27% and 5 (2%) patients
developed daptomycin nonsusceptible enterococcal strains while on HD-daptomycin. Seven patients (3%) had creatine phosphokinase (CPK) elevation, yet no HD-daptomycin regimen was discontinued due to an elevated CPK and
all patients were asymptomatic. Overall, there was a high frequency of clinical success and microbiological eradication in patients treated with HD-daptomycin for enterococcal infections, even in patients with complicated and difficult to treat infections. No adverse event-related discontinuation of HD-daptomycin was noted. HD-daptomycin
may be an option for the treatment of enterococcal infections.
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INTRODUCTION
Infections with multidrug-resistant Gram-positive organisms are becoming highly prevalent(1). In particular, vancomycin-resistant enterococci (VRE) infections are difficult to treat and have been associated with multiple patient
1

DIGITALCOMMONS@WSU | 2013

comorbidities and prolonged duration of hospitalization,
with the predominant pathogens being Enterococcus faecalis and Enterococcus faecium(2, 3). In fact, Enterococcus spp. Are the second most common nosocomial bloodstream pathogen isolate in the United States(4), with VRE
frequencies in intensive care units (ICU) exceeding 30%(5).
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Unfortunately, there are limited effective therapeutic options for VRE infections.
Currently, linezolid is approved by the US Food and
Drug Administration (FDA) for the treatment of VRE infections; however, several limitations exist with this
agent(6). Studies evaluating linezolid for the treatment of
VRE faecium bloodstream infection (BSI) have revealed
clinical success frequency ranging from 58% to 78%(7, 8).
However, reports of linezolid resistance have emerged in
VRE, with an incidence as high as 20%(9). Moreover,
prolonged treatment with linezolid can lead to myelosuppression, including neutropenia, thrombocytopenia, and
anemia, which are frequent comorbid conditions already
present in many patients with VRE infections(6, 10). Lastly, linezolid is bacteriostatic against enterococci(6) and in
serious infections (e.g. prolonged VRE bacteremia specifically endocarditis) a bactericidal agent is preferred(11).
Daptomycin is a concentration-dependent bactericidal
agent currently approved at 4 and 6 mg/kg daily for the
treatment of skin and skin-structure infections (SSSIs) and
Staphylococcus aureus bacteremia, respectively(12, 13).
Both in-vivo and in-vitro studies have revealed that using
higher dosages of daptomycin increased both the degree
and speed of bactericidal activity due to its concentrationdependent pharmacodynamic mechanism. Further, high
dosages can decrease the emergence of resistance in Staphylococcus aureus(14). Daptomycin possesses similar and
potent activity against enterococci and is FDA approved
for the treatment of SSSIs including those caused by vancomycin-susceptible E. faecalis(15). However, due to intrinsically lower susceptibility in enterococci compared to
staphylococci, minimum inhibitory concentrations (MIC)
tend to be at 2 mg/L suggesting larger doses of daptomycin
(approximately 8 mg/kg daily) may be necessary to obtain
similar kill ratios to staphylococci(16). Currently, there are
no clinical dosing recommendations for the use of daptomycin against enterococci, and most dosages reported via
case reports indicate that a median dose of 6 mg/kg is most
frequently used(17, 18). The emergence of resistance in
enterococci to daptomycin has been reported; notably,
these patients have had complicated infections (e.g., osteomyelitis, medical device infections, endocarditis) and
have been treated with daptomycin at dosages of 6 mg/kg
or less(19).
Several case reports, registries and small cohort studies have observed positive clinical outcomes and have suggested the use of higher doses of daptomycin for enterococcal infections(20-23). Gallagher and colleagues performed a retrospective analysis of patients with VRE BSI
treated with daptomycin and concluded that clinical success was associated with a daptomycin dose of ≥ 6 mg/kg
(aOR 7.29, 95%; CI 1.02-52.0)(24). It is possible that
higher dosages of daptomycin in VRE infections may improve the efficacy of this agent and prevent the emergence
of resistance during therapy. Our previous multi-center
observational study examining high-dose daptomycin for
the treatment of infections caused by Gram-positive organ2
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isms suggested that this approach may be both efficacious
and safe(21). However, staphylococci were the primary
pathogens in that cohort; therefore, a focused evaluation of
high-dose daptomycin in serious enterococcal infections
was not possible. The objective of the present study was to
evaluate the safety and effectiveness of high-dose daptomycin therapy (> 6 mg/kg by total body weight) in patients with enterococcal infections in a large multi-center
cohort of patients.
METHODS
A multi-center, retrospective cohort was conducted from
January 2005 to October 2012 and included adult patients
treated with daptomycin at dosages of > 6 mg/kg (total
body weight) and with documented infection with enterococci. The study population included patients > 18 years
of age with enterococcal infections at any site who received daptomycin > 6 mg/kg per dose for at least 3 consecutive days (≥ 72 hours). Patients were excluded if they
had a diagnosis of pneumonia or urinary tract infection in
the absence of enterococcal bacteremia, or received any
form of dialysis (e.g., hemodialysis, continuous ambulatory
peritoneal dialysis, and continuous renal replacement therapy). Data were collected retrospectively using a standardized, electronic tool to capture demographics (e.g., age,
gender, weight, renal function), infection site, diagnosis,
severity of illness at the initiation of high-dose daptomycin
therapy as determined by APACHE II score, comorbid
conditions, prior and concomitant antimicrobial use, surgical procedures within the previous 30 days, duration of
therapy, length of hospital stay, 30-day mortality and overall clinical outcome as ascertained by the treating medical
team. Safety data was also collected using adverse event
reporting in the medical record.
Clinical assessments were determined at the end
of daptomycin therapy. Safety and adverse events were
evaluated in all patients, while effectiveness was only determined in patients with adequate medical record documentation to determine clinical response. Clinical outcomes were characterized as follows: cure: clinical signs
and symptoms resolved and/or no additional antibiotic
therapy necessary, or infection cleared with negative cultures reported at the end of daptomycin therapy; improved:
partial resolution of clinical signs and symptoms and no
additional antibiotic therapy necessary at the end of daptomycin therapy; failure: inadequate response to daptomycin therapy or resistant, worsening, or new/recurrent signs
and symptoms or a positive culture reported at the end of
therapy(20-22, 25). Patients with non-evaluable outcomes
were those for whom medical records did not contain all
necessary information to determine response at the end of
inpatient daptomycin therapy. Additional clinical assessments included the presence and duration of the following:
fever (temperature > 38.30 C), leukocytosis (> 10
cells/mm3), ICU admission, mechanical ventilation, positive blood culture (time from 1st positive blood culture to
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Table 1
Baseline demographic and clinical characteristics.
Characteristics

Median (IQR) or n (%)
n = 245
58 (49-65)
9 (6-14)
76.2 (61.3-93.2)
69 (43.6-97.3)
131 (53.5)
207 (84.5)
53 (23.3)
51 (20.8)
87 (35.5)
48 (19.6)
38 (15.5)
48 (19.6)
53 (21.6)
125 (51)
85 (34.7)

Age, years
APACHE II Score
Weight, kilograms
Creatinine Clearance
Male
Prior Hospitalization
Prior Surgery
Neutropenia
Diabetes
Renal Disease
Liver Disease
Solid Organ/BMT
Chemotherapy and/or Radiation
ICU admission
Mechanical ventilation
Antibiotic Exposure Prior Admission
Prior Vancomycin
108 (44.1)
Prior Daptomycin
13 (5.3)
Prior Linezolid
32 (13.1)
Antibiotics Given Before High-Dose DAP*
Linezolid
57 (23.3)
VancomycinΔ
25 (10.2)
Low-Dose Daptomycin (≤ 6mg/kg)
11 (4.5)
Quinupristin/Dalfopristin
5 (2.0)
Tigecycline
3 (1.2)
Types of Infections
Intra-abdominal
35 (14.3)
Bone or Joint
25 (10.2)
Skin or Wound
11 (4.5)
Meningitis
1 (0.4)
Bloodstream Infection
173 (70.6)
IV catheter
66 (38.2)
Endocarditis
15 (8.7)
Intra-abdominal
32 (18.5)
Skin or Wound
13 (7.5)
Urinary
10 (5.8)
Bone or Joint
5 (2.9)
Prosthetic Device
5 (2.9)
Unknown
27 (15.6)
*Antibiotics given during hospitalization of enterococcal infection that has in-vitro activity
against enterococci; Δevaluated in vancomycin-susceptible enterococci; BMT = bone marrow
transplant; ICU = intensive care unit; DAP = daptomycin; IV = intravenous

first day of 48 hours of negative cultures), site(s) of infection determined by the diagnosing practitioner’s discretion,
with the exception of specific definitions for endocarditis(26), osteomyelitis(27), and uncomplicated and complicated bacteremia(13). Duration of bacteremia was calculated as the number of days between the first positive blood
culture and the first negative blood culture result.
Microbiological Assessment
Microbiologic data were obtained from available culture
data during hospitalization, except for patients with osteomyelitis where culture data may include those from outpatient clinic visits, if available. Microbiologic response was
defined as organism eradication, organism persistence, or
no follow-up culture data available. Eradication was de3
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fined as elimination of the organism while on high-dose
daptomycin and persistence was defined as failure to eradicate the organism at the end of high-dose daptomycin therapy(21, 25). Organism identification, local susceptibility
data and baseline blood isolates were collected, if available,
and evaluated for extended microbiological assessment and
verification at a central research laboratory facility (AntiInfective Research Laboratory, Wayne State University).
For these isolates, daptomycin and vancomycin susceptibility testing were performed by broth microdilution (BMD)
and by Etest according to Clinical Laboratory Standards
Institute guidelines and manufacturer instructions (bioMerieux, Durham, NC)(28), respectively. If the isolate
was not available, the susceptibility interpretation and
methodology were recorded from the referring institution.
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Table 2
Baseline vancomycin and daptomycin minimum inhibitory concentration.
DAP MIC (mg/L)
0.25
0.38
0.5
1
1.5
Enterococcus faecium
≤4
---1
1
VAN
MIC
16-Aug
---(mg/L)
≥32
---8
6

2

3

4

8

-38

-1
11

1
2
53

--1

Enterococcus faecalis
≤4
VAN
MIC
16-Aug
(mg/L)
≥32

--1

--1

1
-1

2
-3

--4

1
-4

----

--2

----

Enterococcus spp.
≤4
VAN
MIC
16-Aug
(mg/L)
≥32

--1

----

1
---

--1

--2

--1

--2

-1
3

----

14

62

1

Total
2
1
3
15
13
44
n = 155
VAN = vancomycin, DAP = daptomycin, MIC = minimum inhibitory concentration

Safety Assessment
All adverse events, including serious adverse events, were
evaluated for all subjects who received at least one dose of
daptomycin therapy. Adverse events were recorded only if
a direct causal relationship to daptomycin was suspected
and documented in the patient’s medical chart by the primary team. Creatine phosphokinase (CPK) levels were
assessed by evaluating any abnormal value or change from
baseline, if available. CPK elevation was defined in previous literature based on 2 sequential measurements during
the period after 3 doses to 3 days after therapy(29). Patients with unexplained signs and symptoms of myopathy
in conjunction with a CPK elevation ≥ 1000 IU/L (~ 5X
ULN) or asymptomatic patients with CPK ≥ 2000 IU/L (>
10X ULN) were reported in further detail(15).
Statistical Analysis
SPSS Statistics, version 20.0 (IBM SPSS Inc., Chicago, IL)
was used to perform descriptive statistics including data
frequencies and distributions for categorical data; median
and interquartile range (IQR) for continuous data. Daptomycin dose and maximum observed CPK levels were
analyzed for relationship by using the Spearman’s rank
correlation. In addition, various MIC testing methods (automated institutional MIC vs. BMD and Etest) were analyzed for relationship by using Spearman’s rank correlation.
Clinical outcome was compared by Pearson’s chi-square in
relation to daptomycin MIC groups (≤ 2 mg/L versus > 2
mg/L).
RESULTS
A total of 245 patients with enterococcal infections received high-dose daptomycin during the time period stud4
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ied. Demographic and clinical characteristics of the patients are presented in Table 1. A total of 173 patients
(70.6%) had a positive blood culture. Among BSI patients,
97 (56.1%) had complicated bacteremia and 76 (43.9%)
had uncomplicated bacteremia. Concomitant site of BSI
along with the other types of infections are displayed in
Table 1. Two hundred twenty-one (90.2%) patients were
given at least one antimicrobial prior to the receipt of highdose daptomycin for enterococcal infections and the median time to switch to high-dose daptomycin was 4 days
(IQR 2-6.5). The median dose and hospital duration of
high-dose daptomycin was 8.2 mg/kg (IQR 7.7-9.7) and 10
days (IQR 6-15), respectively. One hundred and sixtyeight (68.6%) patients had doses of ≥ 8 mg/kg, 34 of these
(13.9%) patients dosed ≥ 10 mg/kg. Two hundred fourteen
(87.3%) patients received daptomycin interval of every 24
hours. Within our whole cohort, 43.7% (107/245) patients
were given another antibiotic concomitantly with daptomycin. The most common type of antibiotic administered concomitantly with high-dose daptomycin was a beta-lactam agent, (76.6%, 82/107) specifically a carbapenem
(39%, 32/82). Most of these patients were given a betalactam as their infections also involved a Gram-negative
pathogen (62.6%, 67/107) along with the enterococcus.
The organism isolated in 245 patients were E. faecium,
E. faecalis, and Enterococcus spp., in 175 (71.4%), 49
(20%), and 21 (8.6%), respectively. Of these enterococci,
204 (83.3%) were vancomycin-resistant according to institutional automated MIC testing methods. Minimum inhibitory concentration (MIC) of vancomycin is displayed in
Table 2. One hundred fifty-five (63.3%) isolates had daptomycin susceptibility available from the medical charts.
The MIC that inhibited growth of 50% (MIC50) and 90%
(MIC90) of baseline enterococci isolates for daptomycin
were 2 mg/L and 4 mg/L, respectively (see Table 2 for the
frequency and distribution of institutional daptomycin
MICs). Seventy-five enterococcal strains were recovered

HIGH-DOSE DAPTOMYCIN AND ENTEROCOCCAL INFECTIONS | A. M. Casapao et al.

Figure 1. Clinical outcome proportion per enterococci species.
Frequency of clinical success for E. faecium, E. faecalis, and Enterococcus spp. were 85.6%, 95.7%, and 94.7%, respectively.

Figure 2. Clinical success stratified by daptomycin minimum inhibitory concentration.
DAP = daptomycin; Frequency of clinical success for daptomycin minimum inhibitory concentration for 0.25, 0.38, 0.5, 1.0, 1.5, 2, 3, 4, 8
mg/L were 100%, 100%, 100%, 93%, 85%, 84%, 91%, 81% and 0%, respectively.

for extended microbiologic assessment with BMD and
Etest for vancomycin and daptomycin susceptibility. Thirty-seven (49.3%) isolates were E. faecium, 29 (38.7%)
were E. faecalis, and 9 (12%) were Enterococcus spp.
Overall, 56 (74.6%) were VRE confirmed by both BMD
and Etest. The MIC50 and MIC90 for these 75 enterococci
isolates for daptomycin by both BMD and Etest were 1
mg/L and 2 mg/L, respectively. The median daptomycin
MIC for E. faecium by BMD and Etest were 2 mg/L (range
of 0.25-4 mg/L) and 2 mg/L (range of 0.5-4 mg/L), respectively. E. faecalis median daptomycin MIC by BMD and
Etest were 0.5 mg/L (range 0.125-2 mg/L) and 1 mg/L
(range 0.25-3 mg/L), respectively. The median daptomycin
MIC for Enterococcus spp. by BMD and Etest were 1
mg/L (range 0.5-2 mg/L) and 1.5 mg/L (range 0.5-3 mg/L),
respectively. Thirty-one enterococci isolates had a reported daptomycin MIC from the institution and a correlation
of daptomycin BMD and Etest method was observed with
Spearman’s rank correlation coefficient of 0.53 (p = 0.002)
and 0.42 (p = 0.019), respectively.
5
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Two hundred and eighteen (89%) patients were clinically evaluable; with 147 (67.4%) patients were cured and
46 (21.1%) improved from their enterococcal infection.
Clinical success(21, 22) was evaluated as the combined
total of patients cured or improved; overall a total of 193
(88.5%) patients achieved clinical success. Proportion of
clinical success by enterococci species is described in Figure 1, which displays a difference in clinical success for E.
faecium versus E. faecalis. One hundred thirty-seven
(62.8%) patients had clinical outcomes available with daptomycin susceptibility. Stratification by daptomycin MIC
is displayed in Figure 2, and demonstrated the variability in
outcome as it relates to MIC. Clinical success did not differ between daptomycin MIC groups with 53.4% and 46.6%
for MIC ≤ 2 mg/L and MIC > 2 mg/L group respectively (p
= 0.371). One hundred and ninety-one (78%) patients
were microbiologically evaluable since follow-up cultures
were available, and overall 177/191 (92.7%) patients had
microbiological eradication with high-dose daptomycin.
Of the microbiologically available patients, 32/33 (97%)
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Figure 3. Maximum observed creatine phosphokinase level.
CPK = creatine phosphokinase; HD DAP = high dose daptomycin

with E. faecalis, 134/147 (91.2%) with E. faecium, and
11/11 (100%) with Enterococcus spp. had microbiological
eradication. The median time to clearance of blood cultures
was 3 days (IQR 2-5). Of the 14 patients with microbiologic persistence, 10 (71.4%) were complicated bacteremia,
sites of infection included: 1 (7.1%) osteomyelitis, 2
(14.7%) skin and wound infection, 5 (35.7%) intraabdominal infection, 4 (28.6%) IV catheter related infection, 1 (7.1%) left ventricular assist device and 1 (7.1%)
right-sided infective endocarditis. Median duration of fever and leukocytosis during the enterococcal infection was
3 days (IQR 1-6) and 7 days (IQR 2-14.3), respectively.
Median ICU length of stay and total length of stay was 8
days (IQR 3-15) and 22 days (IQR 13-39), respectively.
Among the patients admitted to the ICU 85/125 (68%)
were mechanically ventilated with median duration of mechanical ventilation was 8 days (IQR 2-14). All-cause inhospital mortality was 19.6% (48/245) of patients. Of
these 48 patients, 42/48 (87.5%) had E. faecium isolated,
46/48 (95.8%) had VRE isolated, and 41/48 (85.4%) had
BSI. Forty-one of the expired patients were microbiologically evaluable and 34/41 (82.9%) were microbiologically
eradicated. The 30-day all cause mortality rate was 26.5%
(50 patients) for the 189 patients (77.1%) who had followup.
Overall, no patients experienced an adverse event attributed to high-dose daptomycin therapy. Baseline and
subsequent CPK levels were available for 220 (89.8%)
patients. Fifty-four (22%) were receiving concomitant 3hydroxy-3methylglutaryl-coenzyme A reductase inhibitors
(statins) and 20 (8.2%) patients were placed on intramuscular injections while on high-dose daptomycin. Seven
(3.2%) patients had CPK elevations from baseline; one
6
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patient had a baseline CPK ≥ ULN that increased to 5x
ULN while on high-dose daptomycin and the remaining six
patients had a baseline CPK ≤ ULN that increased to 3x
ULN while on high-dose daptomycin. A distribution of
observed maximum CPK level after 3 days of high dose
daptomycin stratified by daptomycin dosages is characterized in Figure 3. No apparent relationship between highdose daptomycin and maximum CPK level was observed
(Spearman’s rank correlation coefficient of 0.07, p = 0.28).
Of interest, one patient who had a baseline CPK level of ≥
10x ULN saw a decrease in CPK to a level of 753 IU/L
after 6 days of high-dose daptomycin (10.4 mg/kg every 24
hours) and remained asymptomatic throughout therapy.
There was no reported myopathy or myositis while on
high-dose daptomycin. All patients with CPK levels ≥ 5x
ULN were asymptomatic and no patients were reported to
have a CPK level increase to ≥ 10x ULN while on daptomycin. High-dose daptomycin was observed in one patient case to be safe up to 15.7 mg/kg (every 24 hours) for
up to 14 days when used to treat VRE faecium complicated
bacteremia from an abdominal source; the highest CPK
level observed was 383 IU/L. The highest observed patient
weight was 164 kg, who received daptomycin 8.2 mg/kg
(every 24 hours) for 12 days and with no observation of
CPK elevation for the treatment of VRE faecium infective
endocarditis with the highest CPK level observed at 26
IU/L.
Daptomycin nonsusceptibility was identified in six patients by the institution’s automated MIC testing system or
by Etest methodology; one isolate was found to be nonsusceptible in the initial blood culture and five strains developed nonsusceptibility during daptomycin therapy. One
patient had a VRE faecium initial daptomycin MIC of 8
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Table 3
Patients with VRE faecitum infections that developed nonsusceptibility to daptomycin.
Infection

Dose of HDDAP (mg/kg)

Baseline DAP
MIC (mg/L)

Days to MIC change
while on HD-DAP

Subsequent
DAP MIC (mg/L)

Outcome

Complicated IV catheter
related BSI

8.2

2*

16

> 4*

Added gentamicin but expired
during hospitalization

Complicated IV catheter
related BSI

8.2

4*

13

> 4*

Discharged with HD-DAP with
gentamicin
DNS identified after D/C
N/A for 30 days F/U
Complicated Prosthetic
6.17
1*
8
> 4*
Switched to LIN and cleared
Device related BSI
BSI
N/A for 30 days F/U
Complicated BSI from
10.1
4#
58
32#
Switched to Quinupristin/
skin/wound
Dalfopristin and cleared BSI
Alive at 30 days F/U
Intra-abdominal
7.5
2#
13
24#
Switched to LIN and not other
follow-up cultures
Alive at 30 days F/U
HD-DAP = high-dose daptomycin; DAP = daptomycin; MIC = minimum inhibitory concentration; IV = intravenous; BSI = bloodstream infection;
DNS = daptomycin nonsusceptibility; D/C = discharged from hospital; LIN = linezolid; N/A = not available; * = MIC identified by automated
testing method from institution; # = MIC identified by Etest testing methodology

mg/L treated with vancomycin for three days and switched
to high-dose daptomycin (7.94 mg/kg every 24 hours) for
right-sided infective endocarditis once VRE was identified.
Daptomycin was later switched to linezolid after seven
days of high-dose daptomycin therapy and blood cultures
cleared after three days of linezolid therapy (linezolid MIC
of 2 mg/L). Five (2%) patients developed nonsusceptibility to daptomycin, with all isolates being VRE. faecium.
These five patients were treated with high-dose daptomycin and description of infection, daptomycin dosages, MIC
data, and outcome is described in Table 3. None of these
patients were given a beta-lactam concomitantly with highdose daptomycin.
DISCUSSION
This study is the largest evaluation of a cohort of patients
treated with high-dose daptomycin for enterococcal infections. Our patient population demographics were very
similar to prior studies evaluating enterococcal infections,
specifically with VRE, in parameters such as ICU admission, previous vancomycin use, mechanical ventilation,
and malignancy(30, 31). Within our cohort, 91 (37.1%)
patients were switched to high-dose daptomycin following
prior therapy with in vitro activity (e.g. linezolid for VRE
or vancomycin for vancomycin-susceptible enterococci);
82 (33.5%) were administered high-dose daptomycin as a
second-line agent and 9 (3.7%) were provided high dose
daptomycin as a third-line agent. The majority was initially treated with high-dose daptomycin for enterococcal infections that was associated with a high frequency of clinical success similar to previous literature regarding the use
of high-dose daptomycin(20, 21). A subgroup analysis of
our data revealed that enterococcal BSI patients had a
higher percentage of severe complicated infections such as
infective endocarditis and intra-abdominal infections compared to previous publications(22, 24). We noted that a
7
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higher percentage of patients with enterococcal BSI tended
to have comorbid conditions such as transplantation, diabetes and liver disease (data not shown). We also found that
more patients received daptomycin in the ICU compared to
the Cubicin® Outcomes Registry and Experience (CORE)
study (53.2% vs. 27%) for treatment of enterococcal bacteremia(22). Our data had similar clinical success frequencies compared to the CORE data(22); in contrast, a higher
frequency of microbiological cure (92.7%, 152/164) was
observed compared to previous literature(21, 24). This
improved outcome suggests a higher dose of daptomycin
may be a favorable treatment option for complicated enterococcal BSI since the median dose of daptomycin for enterococcal BSI in our patients were higher compared to the
CORE data, 8.2 mg/kg (range 6.02-15.70 mg/kg) and 6
mg/kg (range 2.9-14.8 mg/kg), respectively.
The treatment options for VRE BSI are limited. Although FDA approved for the treatment of VRE infections,
including concomitant BSI due to E. faecium, linezolid is
bacteriostatic(6). A retrospective cohort analysis by Crank
and colleagues compared linezolid to daptomycin for VRE
BSI and found no statistical difference in mortality, 29.4%
vs. 46.3%, p = 0.10(32). The mortality was higher in the
daptomycin group by Crank and colleagues but there were
significant differences between the two treatments groups
in baseline characteristics with a higher proportion of the
daptomycin group having shock and have received previous treatment. Our enterococcal BSI hospital mortality
was 23.7% (41/173), lower compared to Crank and colleagues retrospective cohort study. In addition, a retrospective study by Mave and colleagues compared the clinical outcomes of linezolid and daptomycin and found no
significant difference between the two groups(33). Our
study’s characteristics were similar to Mave and colleagues’
retrospective study (not shown) along with the frequency
of mortality in VRE BSI, 27% (40/148) and 26.7% (8/30),
respectively. After reviewing all of these factors, the fre-
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quency of microbiological cure was much higher in our
study compared to Mave and colleagues for the treatment
of VRE BSI with daptomycin. This may suggest that highdose daptomycin may be a favorable option for the treatment of VRE BSI.
Combination therapy of daptomycin and another antibiotic such as rifampin, gentamicin, linezolid, or a betalactam may also be an option for enterococcal infections,
especially for severe or refractory VRE BSI(34, 35). Of
interest, within our cohort of patients that were concomitantly administered a beta-lactam, 89.1% (41/46) of the
VRE BSI patients had clinical success similar to recent
publication(36). This may be of interest, from a recent
data describing a positive outcome in beta-lactams and
daptomycin used in the clearance of refractory VRE bacteremia. It is unknown if the standard dose of daptomycin (6
mg/kg) in combination with a beta-lactam maybe a viable
option compared to high-dose daptomycin but further research is necessary to evaluate the impact of concomitant
beta-lactams with daptomycin especially in serious VRE
infections and with various dosages of daptomycin (low vs.
high-dose). Our data may show a high frequency of success but this was not an a priori focus for data collection.
Even if these enterococci are resistant to beta-lactams including ampicillin, beta-lactams appears to enhance the
activity of daptomycin through reduction in net positive
surface charge(35).
Overall, all patients tolerated high-dose daptomycin
and no adverse events were reported while on daptomycin.
CPK levels were obtained in approximately 90% of our
patient population. Prior studies have reported high dosages of daptomycin to be safe with no elevations of CPK
concentrations while on therapy(23, 37), although others
have reported CPK elevations that led to the discontinuation of high-dose daptomycin due to musculoskeletal
symptoms or related adverse events(20, 38, 39). Recent
data have reported that high-dose daptomycin may elevate
CPK level at an incidence of 2.5-8.3%(39) but no patients
reported symptoms consistent with muscle toxicity(21, 40).
This finding is consistent with our data, demonstrating
high-dose daptomycin to be well tolerated. Within our
study, the highest daptomycin dose given to a patient was
15.7 mg/kg and the longest duration of therapy given to
another patient was 128 days; these two patients tolerated
high-dose daptomycin for a prolonged duration, remained
asymptomatic and neither experienced a CPK elevation.
Additional study supports that high-dose daptomycin may
be tolerable and does not necessarily have a dose or duration-dependent relationship to CPK elevation(41).
Our study is a multicenter observational investigation
that incorporates a diverse cohort of adult patients across
the United States; however this retrospective design does
have some limitations. Our study design is descriptive and
therefore we were not able to compare our results with
those derived from patients receiving lower dosages of
daptomycin or another anti-VRE agent such as linezolid. In
addition, not all patients had CPK levels collected to eval8
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uate for potential elevation although it is interesting to note
that all patients evaluated were asymptomatic and no patient discontinued therapy while on high-dose daptomycin.
On account of this study’s retrospective nature, it is difficult to detect other possible adverse events and there could
have been adverse events that were not attributed to daptomycin.
In conclusion, these results suggest that high-dose
daptomycin may be an option for the treatment of enterococcal infections, including VRE BSI. This study also
suggests that high-dose daptomycin may provide a high
frequency of clinical success along with microbiological
eradication, despite significant comorbid conditions. Since
high-dose daptomycin appears to be a safe, effective, and
tolerable treatment option, further prospective studies of
high-dose daptomycin for treatment of VRE infections is
warranted.
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